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Abstract 
Circulating microRNAs (miRNAs) have emerged as excellent candidates for cancer biomarkers. 
Several recent studies have highlighted the potential use of saliva for the identification of miRNAs as 
novel biomarkers, which represents a great opportunity to improve diagnosis and monitor general 
health and disease. This review summarises the mechanisms of miRNAs deregulation in cancer, the 
value of targeting them with a therapeutic intention and the evidence of the potential clinical use of 
miRNAs expressed in saliva for the detection of different cancer types. We also provide a 
comprehensive review of the different methods for normalising the levels of specific miRNAs 
present in saliva, as this is a critical step in their analysis, and the challenge to validate salivary 
miRNAs as a reality to manage cancer patients. 
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Introduction 
Detection of cancer in the early stages is 
paramount for determining the prognosis, therapeutic 
interventions, survival rates and recurrence of the 
disease [1]. Numerous researchers have focused on 
finding specific biomarkers of disease in body fluids 
such as blood, urine or cerebrospinal fluid [2–4]. 
Recently, several studies have highlighted the 
usefulness of saliva for identifying biomarkers, noting 
that it represents a great opportunity to improve 
diagnosis and monitoring of general health and 
disease [5–7].  
MicroRNAs (miRNAs or miRs) constitute one of 
the most abundant classes of gene-regulatory 
molecules. Different mechanisms have been 
established as responsible of the miRNAs 
deregulation in cancer. Genetic alterations such as 
chromosomal rearrangements, genomic amplificat-
ions, deletions or point mutations have been 
established to play an important role in cancer 
initiation and progression through the aberrant 
expression of miRNAs located in these affected 
regions and, subsequently, by the deregulation of 
their downstream mRNAs targets [8]. Besides, a 
substantial number of miRNA genes are subjected to 
epigenetic alterations such as DNA hypermethylation 
of tumor suppressor miRNAs, extensive genomic 
DNA hypomethylation and alteration of histone 
modification patterns. Altogether, these events can be 
related with aberrant miRNA expression in cancer [9, 
10]. miRNA biogenesis is a complex phenomenon 
where several transcriptional and post-transcriptional 
factors are involved. Despite their small size, miRNA 
production, maturation, and regulatory function 
require the action of a large number of proteins, 
including the two RNase III proteins, DROSHA and 








generally transcribed by the RNA polymerase II (Pol 
II), generating a long transcript called primary 
miRNA (pri-miRNA). The processing of pri-miRNA 
to pre-miRNA occurs within the nucleus by the 
microprocessor complex (including DROSHA) and, 
after exportation to the cytoplasm, pre-miRNA is 
processed to the mature miRNA by DICER RNase. 
The mature miRNA along with AGO proteins form 
miRISC complex, which drives the specific silencing 
of the targeted mRNAs [11]. In oncogenesis, several 
mutations have been found in components of the 
miRNA biogenesis machinery as in DROSHA and 
DICER1, which have been characterized to affect to 
the expression of several miRNAs in cancer [12]. In 
addition, at transcriptional level, several factors have 
been described to modulate miRNA levels. For 
example, the oncogene MYC regulates the 
transcriptional activation of miR-17-92 cluster, an 
oncogenic miRNA over-expressed in several 
malignances [13]. Another example of cancer- 
involved transcriptional regulation of miRNA genes 
is the tumor-suppressor protein p53 that promotes the 
transcription of all miR-34 family members [14]. Due 
to the important role of miRNAs in cancer biology, 
future work will uncover additional pathways that 
regulate the expression of individual miRNAs or 
miRNA clusters in tumourigenesis. 
In cancer biology, miRNAs have been 
established as key molecular components in tumour 
growth, invasion, angiogenesis, and immune evasion 
[15]. miRNAs have the ability to act as oncogenes or 
tumour suppressor genes in different steps of the 
tumourigenic process, affecting several cell-signaling 
pathways essential to carcinogenesis. Since miRNAs 
regulate important cellular processes by regulating 
multiple targets, anticancer therapies based on 
miRNAs are now under investigation. For the 
treatment of cancer, there have been discovered 
different potential therapeutic strategies as the 
following: RNA interference (RNAi)-based therapy 
(sandwich and multiplex RNAi inhibition strategy), 
miRNA inhibition therapy and miRNA mimetic 
agents [16]. Sandwich RNAi inhibition strategy 
focuses on the use of multiples agents to target one 
specific molecular defect whereas multiplex RNAi 
inhibition strategy targets multiple molecular defects 
accumulated in the same pathway of a specific cancer 
[17]. In the second RNA therapeutic drugs, specific 
miRNAs (anti-miR oligonucleotides, locked nucleic 
acid anti-miRNAs, antagomiRs, miRNA sponges, 
miRNA masks and small molecule inhibitors of 
miRNAs) act upon the mature miRNA inhibiting the 
interaction of that miRNA with its target mRNA 
[18–21]. For a similar purpose, it has emerged the 
“SMIR-approach”, a novel inhibitory-miRNA therapy 
based on small molecule inhibitors of miRNAs 
(SMIRs) that act inhibiting miRNA biogenesis or 
impeding miRNA-target interaction [22]. Another 
therapeutic alternative is the “miRNA mimics”, which 
goal is to recover the function of tumour suppressive 
miRNAs using synthetic miRNA-like molecules [23]. 
Nevertheless, the study of miRNA-based therapies is 
still in its infancy and side effects of these therapies 
need a more exhaustive evaluation. Research efforts 
must be addressed to the research of miRNA-based 
targeted therapies for cancer since they could 
represent a great advance to personalized medicine 
for cancer treatment [16]. 
Saliva has a very complex composition including 
enzymes, antibodies, hormones, antimicrobial elem-
ents and cytokines [24]. As a liquid biopsy, saliva 
presents many advantages over blood as collection is 
easy, safe, non-invasive and cost-effective [25]. 
Salivary diagnostic studies have reported the 
existence of several molecular indicators of local and 
systemic disorders, including cancer [26]. In the recent 
years miRNAs have emerged as excellent candidates 
for cancer biomarkers due to their remarkable 
stability and resistance to degradation [27–29]. 
miRNAs are small, noncoding RNA molecules 
consisting of 18-22 nucleotides that act as regulators of 
many cellular processes [30]. They are one of the most 
abundant classes of gene-regulatory molecules 
involved in gene expression [15]. A single miRNA can 
regulate the expression of multiple genes involved in 
various cellular process associated with cancer 
development [31, 32]. Nowadays it is well known that 
miRNAs play an important role in the initiation and 
progression of cancer and depending on their 
transcript targets they act as “oncomiRs” or “tumour 
suppressive miRNAs” [31, 33]. In this sense, 
carcinogenesis is associated with aberrant expression 
of miRNA profiles. Alterations in miRNAs could arise 
from various genetic alterations such as those 
involving chromosomal abnormalities, genomic 
mutations, epigenetic changes and anomalies in 
miRNA biogenesis [34]. Biologically, miRNAs have 
been identified in twelve body fluids: amniotic fluid, 
breast milk, bronchial lavage, cerebrospinal fluid, 
colostrum, peritoneal fluid, plasma, pleural fluid, 
seminal fluid, tears, urine and saliva [35]. There are 
multiple sources of circulating miRNAs including 
tumour cells, immune cells and blood cells [36, 37], 
and several proposals have been made on how 
miRNAs are released into circulation (e.g. packaged 
into microvesicles or exosomes, or in vesicle-free 
form, that is in association with protein complexes) 
[38]. 
In the last few years it has been reported that 
circulating miRNAs in serum and plasma may serve 




as diagnostic biomarkers [39]. Regarding human 
cancer, several authors [27, 40, 41] have reported 
different levels of salivary expression of miRNAs. 
Hence, saliva has attracted increased attention as a 
novel non-invasive tool for cancer diagnosis. In this 
review we describe findings related to the potential 
clinical use of salivary miRNAs for cancer detection. 
We also provide a comprehensive review of the 
different methods of normalising the levels of specific 
miRNAs present in saliva, as this is a critical step in 
their analysis.  
Circulating miRNAs in saliva 
There are several hypotheses for the presence of 
cell-free nucleic acids and proteins into saliva. These 
molecules could enter into the saliva from the blood 
via various cellular mechanisms, such as transcellular 
(passive intracellular diffusion and active transport) 
or paracellular routes (extracellular ultrafiltration) [7]. 
miRNAs could also be produced locally by apoptosis 
or cell necrosis and they could also be released by 
normal epithelial or cancerous cells in exosomes or 
microvesicles [42–44]. It is important to note that 
circulating miRNAs in saliva could act as signalling 
molecules in the context of cancer biology [45]. 
Numerous studies (Table 1) have identified a 
variety of salivary miRNAs (Figure 1) as promising 
non-invasive diagnostic biomarkers of cancer. Below, 
we summarised these studies according to the tumour 
type, moving from tumours localized close to the oral 
cavity to more distant tumours. 
 
Table 1. Summary of studies with salivary miRNAs identified in different types of cancer. 
Cancer 
Location  
Patients (No) Tumor 
stage 






DP: 12 OSCC, 12 HC 
VP: 50 OSCC, 50 HC 
I-IV miR-200a, miR-125a Downregulated U6-snRNA  [41] 
9 OSCC, 8 OSCC-R, 8 OLP,  
9 HC 
NA miR-136, miR-147, miR-1250, 
miR-148a, miR-632, miR-646, 
miR-668, miR-877, miR-503, 
miR-220a, miR-323-5p,  
miR-24, miR-27b 
Downregulated 
(Upregulated miR-24 and 
miR-27b) 
miR-191  [51] 
20 OSCC, 20 HC, 40 OPMDs, 
20 RAS 
NA miR-21, miR-184, miR-145  Upregulated 
(Downregulated miR-145) 
SNORD68  [53] 
45 OSCC, 10 OVL, 24 HC I-IV miR-31 Upregulated miR-16  [48] 
15 OSCC, 7 HC NA miR-375 Downregulated miR-191  [50] 
DP: 3 TSCC, 4 HC I-III miR-139-5p Downregulated U6-snRNA  [54] 
VP: 25 TSCC, 25 HC 
DP: 5 HNSCC, 5 HC II-IV miR-9, miR-127, miR-191, miR-222 Upregulated SNORD96A  [46] 
VP: 35 HNSCC, 35 HC 
DP: 10 C, 10 BT 
VP: 28 C, 19 BT 





DP: 20 PGNs, 10 HC NA miR-296-5p, miR-1233, miR-1267,  





VP (whole saliva): 46 PGNs,  
14 HC 
Oesophageal DP: 7 C, 3 HC I-IV miR-144, miR-10b, miR-451, miR-21 Upregulated miR-16  [27] 
VP: 39 C, 19 HC 
DP: 8C, 4 HC II-IV miR-21 Upregulated miR-16  [64] 
VP: 32 C, 16 HC 
100 C, 50 HC I-II miR-21 Upregulated miR-16  [65] 
67 C, 50 HC NA miR-144 Upregulated NA  [67] 
5 C, 5 HC NA miR-196a Upregulated miR-16  [68] 
Pancreatic DP: 8 C, 8 HC 
VP: 40 C, 20 BT, 40 HC 
I-III miR-3679-5p, miR-940 Downregulated (miR-3679-5p) 
Upregulated (miR-940) 
U6-snRNA  [28] 
30 C, 32 HC NA miR-17, miR-21, miR-181b, miR-196a Upregulated miR-16  [69] 
7 C, 4 P, 2 IPMN, 4 HC NA miR-21, miR-23a, miR-23b, miR-29c, 
miR-216 
Upregulated RQ manager 1.2.1 and 
Data Assist v3.0 
(Applied Biosystems) 
 [40] 
12 C, 13 HC II-IV miR-1246, miR-4644 Upregulated U6-snRNA  [70] 
Prostatic NA (Supernatant and pellet) NA miR-21, miR-141 Upregulated Exogenous miR-21 and 
miR-141 
 [72] 
Colorectal  34 CRC, 34 HC II-IV miR-21 Upregulated U6-snRNA  [73] 
Abbreviations: DP, discovery phase; VP, validation phase; C, cancer; P, pancreatitis; BT, benign tumour; HC, healthy controls; IPMN, intraductal papillary mucinous 
neoplasia; OSCC, oral squamous cell carcinoma; OSCC-R, OSCC in remission; OPMDs, oral potentially malignant disorders; RAS, recurrent aphthosus stomatitis; OLP, oral 
lichen planus; OVL, oral verrucous leukoplakia; HNSCC, head and neck squamous cell carcinoma; PGNs, parotid glands neoplasms; TSCC, tongue squamous cell 
carcinoma; CRC, colorectal carcinoma; NA, not available. 
 





Figure 1. Salivary miRNAs in cancer diagnosis. 
 
Head and neck squamous cell carcinoma 
According to National Cancer Institute, head 
and neck cancers are a group of cancers that start in 
the tissues and organs of the head and neck, including 
the oral cavity, pharynx, larynx, paranasal sinuses, 
nasal cavity and salivary glands. Salazar et al. [46] 
used a novel saliva-based miRNA biomarker panel to 
detect head and neck cancers located in the oral 
cavity, pharynx, oropharynx and larynx. In a 
discovery phase they selected five miRNAs (miR-9, 
miR-127, miR-134, miR-191 and miR-222) by 
microarray analysis. Differential expression of these 
miRNAs was assessed in confirmation and validation 
phases in independent cohorts. miR-9, miR-191, 
miR-127 and miR-222 were over-expressed in the 
cancer group relative to the control group. An 
independent validation based on the Cancer Genome 
Atlas (TCGA) miRNA-seq data from 334 tumours and 
39 normal tissues showed that miR-9, miR-191 and 
miR-222 were significantly over-expressed in tumour 
samples. The receiver-operating characteristic (ROC) 
curve analysis indicated high discriminatory power 
for miR-9, miR-191 and miR-222 with AUC values of 
0.85, 0.74 and 0.98, respectively. A salivary panel 
formed by the combination of these three miRNAs 
had an AUC of 0.74. The authors also evaluated the 
power of miRNA expression profiles to discriminate 
between head and neck squamous cell carcinoma 
(HNSCC) patients with tumours in different 
anatomical locations (oral cavity, pharynx, 
oropharynx and larynx). miR-222, miR-191 and 
miR-127 differentiated between patients with cancer 
in the oral cavity and pharynx, miR-9 (AUC = 0.77) 
differentiated between oropharynx and larynx cancer 
patients, miR-191 differentiated between oropharynx 
and pharynx patients (AUC = 0.94), and miR-127 
differentiated between pharynx and larynx cancer 
patients (AUC = 1.00). Although this study 
encompassed several types of head and neck cancers, 
oral squamous cell cancer (OSCC) and parotid gland 
tumours are the head and neck cancers most 
commonly investigated using saliva.  
Oral Squamous Cell Cancer 
The first study to identify miRNAs in saliva was 
performed in OSCC [41]. Park et al. [41] analyzed 
saliva supernatant from OSCC patients and observed 
group differences in the level of expression of 
miR-200a and miR-125a. Salivary miRNAs were 
detected in both whole and saliva supernatant, 
although a more diverse miRNA population was 




observed in total saliva, probably because whole 
saliva contains miRNAs from desquamated oral 
epithelial cells [41]. In addition, a variety of miRNAs 
have been reported in metastatic (miR-181 and 
miR-296) and non-metastatic (miR-31 and miR-130b) 
OSCC samples [47]. Liu et al. [48] reported that 
salivary levels of miR-31 were significantly 
upregulated in pre-surgery OSCC patients compared 
with the levels in healthy individuals. In this study, 
not significant differences were observed between 
oral verrucous leukoplakia patients and control 
group, but a significant lower value was observed 
respect to OSCC patients [48]. Expression of miR-31 
was reduced after tumour resection and, indeed, a 
high correlation was observed between salivary and 
plasma levels of miR-31. Interestingly, levels of 
miR-31 were more abundant in saliva than in plasma, 
indicating that salivary miR-31 has potential as a tool 
for diagnosis of pre-cancerous lesions. The reduction 
in miR-31 salivary levels after surgical resection 
suggested a relationship between the tumoural tissue 
and the salivary molecular profile [48]. 
Deregulation of miRNA expression is a complex 
process that contributes to the development of human 
cancer and is associated with the progressive 
accumulation of multiple genetic abnormalities. In 
oral carcinogenesis, epigenetic mechanisms such as 
altered DNA methylation patterns play an important 
role in silencing tumour-suppressive miRNAs [49]. 
Wilkund et al. [50] analyzed miRNA expression and 
changes in DNA methylation in OSCC patients rinsed 
with a PBS solution (oral rinse) and saliva. Levels of 
miR-375 were lower in the cancer group than the 
control group in both types of sample. In oral rinse, 
patients’ miR-200a levels were lower than those of the 
control group, and miR-200c-141 CpG methylation 
was significantly higher. The authors suggested that 
oral rinse could be a more sensitive source of 
OSCC-specific miRNA and DNA methylation, due to 
the exposure of the buccal epithelia to environmental 
factors [50]. Recently (2014), Momen-Heravi et al. [51] 
reported that 13 miRNAs were deregulated in 
salivary cancer samples compared to controls; of these 
13, only miRNA-24 and miRNA-27b were 
significantly over-expressed. miR-27b had the best 
sensitivity and specificity when it came for 
discriminating OSCC patients from the other groups: 
OSCC vs. healthy individuals: sensitivity = 85.71%, 
specificity = 100%; OSCC vs. OSCC in remission 
(OSCC-R): sensitivity = 85.71%, specificity = 83.33%; 
OSCC vs. oral lichen planus (OLP): sensitivity = 
85.71%, specificity = 100%. Moreover, miR-136 was 
under-expressed in saliva of OSCC patients relative to 
healthy controls, and discriminated between them 
with 88.89% sensitivity and 100% specificity. 
However, it was also found that plasma and tissue 
expression of miR-27b was significantly reduced in 
OSCC patients [52]. The secretion of miRNAs from 
tumour cells into saliva could lead to a difference in 
the expression profile for body fluids and cancer 
tissue. In 2015, Zahran et al. [53] reported that salivary 
levels of miR-21 and miR-184 levels were significantly 
higher in OSCC patients and oral potentially 
malignant disorders (OPMDs) patients than in 
healthy and disease controls, while salivary miR-145 
levels were significantly lower in OSCC and OPMDs. 
ROC analysis indicated the discriminatory power of 
miR-21, miR-145 and miR-184 with sensitivity values 
of 65%, 60% and 80% respectively, and specificity 
values of 65%, 70% and 75% respectively. A 
microarray study of tongue squamous cell carcinoma 
revealed that 183 miRNAs were significantly 
upregulated in the salivary samples of the cancer 
group and 236 miRNAs were significantly 
downregulated. The upregulation of two miRNAs 
(miR-33a-3p and miR-198) and the downregulation of 
one miRNA (miR-139-5p) was validated in 50 saliva 
samples. Salivary expression of miR-139-5p was 
significantly lower in preoperative patients than 
controls, but levels were similar in preoperative and 
postoperative patients. ROC curves showed that 
miR-139-5p differentiated between preoperative 
patients and both healthy individuals and 
postoperative patients, with AUCs of 0.805 and 0.713 
respectively [54]. Importantly, miR-139-5p has an 
anticancer function, playing an important role in cell 
proliferation, apoptosis [55], lymph node involvement 
[56], and metastasis [57]. 
Parotid Gland Tumour 
Matse et al. [58] investigated miRNA profiles in 
whole saliva from patients with malignant or benign 
parotid gland tumours. They found 57 miRNAs 
differentially expressed in the benign and malignant 
tumour groups. Of the 18 verified miRNAs, 
differential expression of nine (namely miR-140-5p, 
miR-374, miR-222, miR-15b, let-7g, miR-132, 
miR-519b-3p, miR-223, and miR-30a-3p) were 
validated in an independent set of samples that 
showed increased salivary levels for those miRNAs in 
patients with a malignant parotid gland tumour. 
Statistically significant levels were observed for 
miR-374, miR-222, miR-15b, let-7g, miR-132, and 
miR-140-5p between benign and malignant parotid 
gland tumour groups. A logistic model consisting of 
four miRNAs (miR-132, miR-15b, miR-140, and 
miR-223) showed 69% sensitivity and 95% specificity 
with an AUC of 0.90 to identify parotid gland 
tumours. Recently, the same research group [59] 
reported new data on miRNA expression profiles for 




whole saliva from patients with parotid gland 
neoplasms. Of the 742 miRNAs analyzed in an 
exploratory phase, eight miRNAs were differently 
expressed in tumour patients and healthy controls. In 
the validation phase, seven miRNAs (miR-296-5p, 
miR-1233, miR-1267, miR-1825, miR-103a-3p, miR-211 
and miR-425-5p) were found to be significantly 
over-expressed relative to controls in whole saliva 
from patients. A logistic regression model containing 
a combination of these seven miRNAs yielded an 
AUC of 0.95, with 93% sensitivity and 86% specificity 
for predicting the presence of a parotid gland 
neoplasm. In comparison, a model based on just 
miR-211 and miR-1233 had sensitivity of 91% and 
specificity of 86%. The authors also analyzed the 
expression of the validated miRNAs in a set of 12 
parotid saliva samples (affected gland and healthy 
gland) and in 14 healthy controls (both healthy 
glands). Only miR-425-5p and miR-1825 were 
expressed in parotid saliva at similar levels to those in 
whole saliva. The absence of miR-103a-3p, miR-211, 
miR-296-5p, miR-1233 and miR-1267 from parotid 
saliva indicates that stimulated and unstimulated 
saliva have different miRNA expression profiles.  
Oesophageal cancer  
Several authors have analyzed the role of miR-21 
and miR-144 in the pathogenesis of oesophageal 
cancer [60–63]. In a two-phase study, Xie et al. [27] 
analyzed miRNA expression in the saliva of patients 
with oesophageal cancer. In a discovery phase, ten 
saliva samples were subjected to microarray analysis 
and five miRNAs (miR-144, miR-10b, miR-451, 
miR-486-5p, and miR-634) were selected for the 
validation phase. miR-21 was also included in the 
validation phase as several authors had shown that its 
expression was aberrant in the plasma and tissue of 
oesophageal cancer patients. Curiously, levels of 
miR-144, miR-10b and miR-451 in whole saliva were 
significantly correlated with levels in saliva 
supernatant. In whole saliva, three miRNAs 
discriminated between oesophageal cancer patients 
and controls: miR-10b, miR-144 and miR-451 had 
sensitivities of 89.7%, 92.3% and 84.6%, and 
specificities of 57.9%, 47.4% and 57.9%, respectively. 
In saliva supernatant, four miRNAs discriminated 
between oesophageal cancer patients and controls: 
miR-10b, miR-144, miR-21 and miR-451 had 
sensitivities of 79.5%, 43.6%, 89.7% and 51.3%, and 
specificities of 57.9%, 89.5%, 47.4% and 84.2%, 
respectively. Cancer stage, pathology type and 
presence of nodal metastases were independent 
factors contributing to variance in salivary levels of 
these miRNAs. 
In a preliminary study, Xie et al. [64] showed 
significant upregulation of miR-21 in saliva 
supernatant from oesophagal cancer patients 
(sensitivity = 87.5%, specificity = 62.5%). Salivary and 
plasma levels of miR-21 have also been evaluated [65]. 
miR-21 plasma and salivary levels were significantly 
higher in cancer samples and there was a positive 
correlation between levels in these two body fluids. 
Interestingly, high plasma levels of miR-21 have been 
associated with poor survival [66]. In another study, 
Wu et al. [67] evaluated the salivary levels of miR-144 
in whole saliva and saliva supernatant from 67 
patients and 50 healthy controls. Levels of miR-144 
were significantly higher in salivary cancer samples 
than control samples, indicating moderate diagnostic 
power with respect to oesophageal cancer, with a 
sensitivity of 74.6% and specificity of 92% for whole 
saliva and a sensitivity of 53.7% and specificity of 94% 
for saliva supernatant. 
Recently, Fendereski et al. [68] observed a 
significant upregulation of miR-196a in tissue tumour 
samples as compared with the normal matching tissue 
from the same patients. Besides, a significantly 
increased expression of miR-196a was found in saliva, 
showing the potential of this miRNA as a diagnostic 
biomarker of oesophageal cancer. 
Pancreatic cancer 
In pancreatic cancer, Gao et al. [69] found 
miRNAs specifically expressed in three different 
groups of ZHENG disease conditions (Shi-Re, Pi-Xu 
and Xue-Yu), which is the cornerstone in traditional 
Chinese medicine. They found significantly higher 
levels of miR-17, miR-21 and miR-181b in patients 
with Shi-Re ZHENG and higher levels of miR-196a in 
patients with Pi-Xu ZHENG. Interestingly, these 
findings indicate that miRNAs may have a role as 
specific biomarkers for different syndromes of 
traditional Chinese medicine. In 2015, Xie et al. [28] 
reported two salivary miRNAs (miR-3679-5p and 
miR-940) as potential non-invasive biomarkers of 
resectable pancreatic cancer. miR-3679-5p was 
significantly found downregulated in pancreatic 
cancer whereas miR-940 was significantly found 
upregulated. A logistic regression model was used to 
evaluate the power of miR-3679 and miR-940 to 
discriminate between various cancer and non-cancer 
groups. The model had 72.5% sensitivity and 70% 
specificity when comparing a cancer group and a 
healthy control group; 62.5% sensitivity and 80% 
specificity when comparing the cancer group and the 
benign pancreatic tumour group; and 70% sensitivity 
and 70% specificity when comparing the cancer group 
with a combined non-cancer group.  
In a recent pilot study, Humeau et al. [40] found 
that relative to controls, miR-21, miR-23a, miR-23b 




and miR-29c were significantly upregulated in saliva 
of pancreatic cancer patients group, with sensitivity 
values of 71.4 %, 85.7%, 85.7% and 57%, respectively, 
and specificity of 100% in all cases. In addition, 
miR-210 and let-7c were upregulated in pancreatitis 
patients compared with a healthy group, and miR-216 
was upregulated in cancer patients relative to the 
pancreatitis group. In an experimental murine model, 
differential expression of miR-21 was validated using 
xerografts of pancreatic cancer cells. The study 
revealed over-expression of salivary miR-21 in 
tumour-bearing mice relative to non-cancer mice, 
indicating that elevation of salivary miR-21 precedes 
systemic cancer markers.  
Recently, Machida et al. [70] analyzed miRNAs 
in salivary exosomes from patients with 
pancreatobiliary tract cancer. Levels of miR-1246 and 
miR-4644 were significantly higher in the cancer 
group than in the control group. ROC curves were 
used to evaluate the discriminatory power of 
miR-1246 and miR-464 and showed AUCs of 0.814 
and 0.763, respectively. Although further 
investigation is necessary, salivary exosomal miRNAs 
has been described as useful biomarkers of pancreatic 
cancer. In addition, Alemar et al. [71] evaluated the 
serum expression profile of five oncogenic miRNAs 
(miR-21, miR-155, miR-196a, miR-200b, and 
miR-376a) and one tumour suppressive miRNA 
(miR-34a). miR-21 and miR-34a were over-expressed 
in cancer samples relative to control samples, with 
AUCs of 0.889 and 0.865, respectively. Levels of 
miR-21 and miR-34a were significantly correlated. 
Serum expression of miR-200a was significantly 
associated with histological grade and tumour 
location. However, although these miRNAs were 
detected in salivary samples, levels were similar in 
cancer patients and controls. 
Prostate cancer  
Hizir M.S. and colleagues [72] evaluated the 
expression of miR-21 and miR-141, two miRNAs 
over-expressed in early and advanced prostate cancer 
patients, respectively. They have demonstrated 
simultaneous detection of endogenous and exogenous 
miR-21 and miR-141 from human body fluids 
including blood, urine, and saliva, by using a 
specially designed biosensing nanographene oxide 
system, which uses two different wavelengths to 
detect miR-21 and miR-141 simultaneously (520 and 
670 nm, respectively). Their approach is faster and 
easier than multiple and simultaneous qPCR 
detection, and can be performed with a portable 
spectrofluorometer; however, improved sensitivity is 
still needed for further clinical application. 
Colorectal cancer  
miR-21 was the first miRNA analyzed in salivary 
samples from colorectal cancer (CRC) patients [73]. 
Several cancer-related genes such as genes for 
phosphatase and tensin homologue (PTEN), 
tropomyosin 1 (TPM1) and programmed cell death-4 
(PDCD4) are regulated by miR-21, which is an 
oncogenic miRNA [74]. Indeed, numerous studies 
have reported increased expression of miR-21 in 
plasma and serum from CRC patients [75–78]. In 
serum, high levels of miR-21 were associated with 
large tumour size, distant metastasis and advanced 
TNM stage [79]. Recently, Sazanov et al. [73] 
evaluated expression levels of miR-21 in plasma and 
saliva samples from CRC patients. In both body 
fluids, median levels of miR-21 were significantly 
higher in the cancer group than in the control group, 
but there were no differences between patients at 
stages II, III and IV. In addition, levels of miR-21 in the 
cancer and control groups were independent of 
gender and age. However, no significant individual 
correlation and linear regression of miR-21 expression 
levels in the plasma and saliva were detected. 
Importantly, miR-21 levels in plasma had a sensitivity 
of 65% and a specificity of 85% for discriminating 
between CRC patients and controls, whereas in saliva 
miR-21 had a sensitivity of 97% and specificity of 91%. 
The high sensitivity and specificity values for salivary 
miR-21 reflected the potential use of this saliva-based 
test as a method of CRC diagnosis. 
MiRNAs normalization strategies in 
saliva  
Normalization is important for accurate 
quantification of RNA levels using reverse 
transcription–PCR (qRT-PCR). The most commonly 
used normalization strategies for expression of 
circulating miRNAs are Global Mean Expression [80], 
exogenous (spiked-in) miRNAs and endogenous 
controls [81]. The most widely used method is 
normalization based on endogenous controls such as 
miRNA, small nuclear RNA (snRNA) and small 
nucleolar RNA (snoRNA) [82]. However, suitable 
reference genes should be selected in order to reduce 
the technical variation and avoid the misinter- 
pretation of the data [80, 82, 83], but there is no 
consensus on which miRNA is best for normalization. 
Researchers select reference genes based on other 
studies [27, 28, 48, 59, 73], or searching stable miRNAs 
in their own samples [51], following the strategy 
described by Vandesompele et al. [84], where stable 
genes across the samples (among other factors) make 
it suitable for their usage as a normalization 
standards. 




The reference genes most commonly used for 
normalization of miRNA expression in saliva are 
miR-16 and miR-191 [27, 48, 50, 51, 64, 69], but also 
two snoRNAs (SNORD68 and SNORD96A) [46, 53] 
and one snRNA (U6) [28, 41, 54, 58, 59, 70, 73]. 
miR-191 has been used as a reference gene for the 
miRNA normalization in oral cancer patients [50, 51]. 
In this sense, Momen-Heravi et al. [51] evaluated 
three miRNAs (miR-16, miR-191 and miR-484) 
generally considered to be stable using the 
NormFinder algorithm. Although miR-16 and 
miR-484 had high stability values, miR-191 had the 
lowest intragroup and intergroup variability 
according to NormFinder, so miR-191 was used as 
reference internal control in their research. 
miR-16 has been selected for miRNAs 
normalization in serum [85] and plasma [76, 86] due 
to its high stability and abundance [33, 76, 86] and is 
the internal control most commonly used for analyses 
of saliva [27, 48, 64, 65, 69]. However, its suitability as 
a reference gene for normalization in saliva has never 
been systematically evaluated. In addition, Chen et al. 
[36] observed that miR-16 and other normalizers such 
as 5S rRNA and U6 were degraded in serum samples. 
In their study levels of the analyzed miRNAs were 
directly normalized to the total RNA amount. Other 
authors have also reported that the levels of U6 are 
unstable, decreasing over freeze–thaw cycles relative 
to miR-16 and miR-24 [87].  
Due to technical variations in sample processing 
and extracellular RNA (exRNA) extraction and 
analysis, proper normalization is critical for consistent 
detection of true biological differences between 
samples, an issue that was also discussed by the NIH 
exRNA consortium [88]. They present a preliminary 
study suggesting that it may be possible, at least in 
plasma, to identify a set of exRNAs with relatively 
stable abundances, which may be used as internal 
reference standards for exRNA quantification. 
Overall, there is no consensus on validated internal 
controls for accurate quantification of the RNA levels. 
This represents a serious problem as many 
researchers use reference genes that have not been 
validated beforehand. 
Salivary miRNAs: onset hypothesis 
Many diagnostic miRNAs have been discovered 
through deep sequencing technologies, and although 
further research is needed to elucidate the complexity 
of the heterogeneous origin of miRNAs in body fluids, 
they provide precise information that could lead to 
early detection and recognition of cancer [89]. 
miRNAs are small RNA molecules that are stable in 
circulation and importantly are protected from 
RNases degradation [90]. Several mechanisms have 
been proposed for circulatory miRNA protection 
against degradation, such as by forming 
ribonucleoproteins complexes (i.e. with AGO2 or 
HDL proteins) or by being incorporated into 
extracellular vesicles (apoptotic bodies, shedding 
vesicles and exosomes) [89].  
Saliva is a proximal body fluid in the oral cavity 
and therefore is intuitively sound for detection of oral 
diseases. Currently, there are several theories and 
studies (including pre-clinical models) supporting 
why saliva is termed as “liquid biopsy”, useful for 
detection of other systemic diseases as well. Some 
studies hypothesize that molecules from the primary 
tumour can be carried in the bloodstream and appear 
altered in saliva from cancer patients compared to 
healthy patients (or patients with benign diseases). 
Gao et al. [91] used induced tumour-bearing mice 
models of melanoma and lung cancer, and defined a 
salivary transcriptome profile associated to each 
tumour-type. Lau et al. [92], by using a pancreatic 
tumour-bearing mice model, revealed the basic 
mechanisms underlying the rationale of salivary 
biomarkers through the hypothesis that exosome-like 
vesicles carry, drive, and deliver tumour markers into 
the saliva. Yet, the lack of certainty and detailed 
mechanistic insights showing how salivary 
biomarkers can reflect disease states elsewhere in the 
body has compromised the scientific acceptance of 
this emerging field in the clinics. The clinical and 
scientific references to saliva for systemic disease 
detection will represent an important step forward 
that will transform molecular diagnostics globally. 
Salivary miRNAs as point-of-care 
systems 
Despite we are far from fully understanding the 
fundamental biology of salivary biomarkers, some 
achievements have been made aiming at developing a 
device for specific salivary biomarkers’ detection. In 
particular, the “Oral Fluid NanoSensor Test 
(OFNASET)” is a prototype nanotechnology point-of- 
care sensor that has the ability to detect multiplexed 
analytes in saliva for oral cancer detection, through 
the combination of mRNA and protein 
electrochemical detection [93]. In addition, a device 
able to detect EGFR mutation at DNA level by using 
patients’ saliva for lung cancer diagnosis, in order to 
reduce the current invasive procedures and reduce 
unnecessary biopsies was developed [94]. More 
recently, another device for oral cancer detection was 
published based on a novel optical microfluidic 
biosensor with highly sensitive organic photodete-
ctors for absorbance-based detection of salivary 
protein biomarkers [95]. The results of measuring IL-8 
and IL-1E protein levels were in agreement with those 




provided by two commercial assays of ELISA thereby 
offering an attractive and cost-effective tool for 
diagnostic or screening purposes at the point of 
care. Several biosensors allowed the detection of 
multiple analytes including DNA, RNA and proteins 
for both oral and systemic diseases [96], including the 
unique study that developed a biosensor system to 
detect salivary miRNAs for prostate cancer detection 
[72]. Continuous research on the field is needed to 
translate salivary diagnostics into a routinely clinical 
practice to improve cancer diagnosis and reduce 
mortality. In turn, the generation of point-of-care 
systems will benefit health system and quality life of 
patients. 
Other sources of extracellular miRNAs 
In addition to saliva, circulating cell-free 
miRNAs previously identified in cells and tissues 
have been also identified in urine, plasma, serum and 
stool as potential diagnostic and prognostic cancer 
biomarkers. In prostate and bladder cancer, numerous 
studies have reported the utility of urine-circulating 
miRNAs as potential biomarkers [97, 98]. In addition, 
urinary miRNAs has been purposed as biomarkers for 
breast, ovarian, hepatocellular and pancreatic cancer 
[99–102]. In plasma and serum, numerous miRNAs 
have been found significantly differentially expressed 
in patients compared with healthy controls in several 
cancers, such as oral [103, 104], breast [105, 106], 
prostate [107, 108] and gastric [109, 110] cancers, as 
well as in oesophageal carcinoma [111, 112], colorectal 
[78, 113], pancreatic [114, 115] and lung [116, 117] 
cancers and hepatocellular carcinoma [118, 119]. 
Nowadays, only few cancer studies have evaluated 
the expression profiles of circulating miRNAs in 
saliva compared to serum or plasma [48, 71, 73]. In 
serum and saliva, Alemar et al. [71] have evaluated 
the expression levels of six pancreatic ductal 
adenocarcinoma-associated miRNAs (miR-21, 
miR-34a, miR-155, miR-196a, miR-200b, and 
miR-376a). Only significant differences were observed 
for serum miR-21 and miR-34a. Conversely, in saliva 
only miR-196a was significantly higher in the control 
group, showing a heterogeneous and almost 
undetectable expression [71]. In OSCC, miR-31 
salivary levels revealed a strong correlation with 
miR-31 serum levels. Besides, saliva presented greater 
amount of miR-31 than plasma, indicating the 
enormous value of saliva as diagnostic biofluid [48]. 
Recently, expression levels of miR-21 were analyzed 
in plasma and saliva of CRC patients. Although, no 
significant individual correlation and linear 
regression of miR-21 expression levels in the plasma 
and saliva were observed, saliva showed a higher 
sensitivity and specificity than plasma for CRC. Thus, 
the diagnostic sensitivity of miR-21 expression in the 
plasma was 65% and specificity was 85% whereas in 
the saliva was 97% and 91%, respectively [73]. 
Overall, miRNAs have demonstrated to be potential 
biomarkers in cancer diagnosis and prognosis, 
although research efforts should be made to improve 
our knowledge about miRNAs biology among 
different body fluids. 
Analysis of microRNAs in body fluids: 
advantages and disadvantages 
MiRNAs in body fluids can provide great 
insights in the advance towards personalized 
medicine. Although there is a long way to go in the 
investigation of extracellular miRNAs till they could 
be used in clinical practice, it seems that nowadays the 
advantages are superior to the disadvantages. One of 
the advantages is that miRNAs present a robust 
stability and resistance to degradation in body fluids, 
showing its potential as tumour biomarkers [120]. The 
non-invasiveness collection and easy reproducibility 
are key factors [121], reinforcing the high value of 
circulating miRNAs as biomarkers for the cancer 
patients’ management. Thus, in human cancer, 
aberrant circulating miRNA profiles allow to know 
the clinicopathological features of the tumour 
non-invasively [122]. In this way, a molecular 
classification based on miRNAs expression profiles 
could be of a great interest for the pathologic 
classification of each tumour [123]. Furthermore, 
miRNA expression has been evaluated in cancer with 
the goal to provide promising biomarkers for the 
early diagnosis [124], prognosis [125], therapy and 
outcome prediction [126, 127]. Nevertheless, one of 
the main handicaps of using circulating miRNA as a 
liquid biopsy is their unknown origin since they can 
come from other sources than tumour cells. Besides, 
non-cancer conditions (diet, exercise, infection and 
hypoxia) can affected to the expression levels of 
circulating miRNAs [114–116]. Fundamental efforts 
should be addressed to develop clinically relevant 
experimental research on miRNA and clinical trials 
with reliability and reproducibility results, taking into 
account the lack of concordance between the labs and 
inability to validate studies reported by other labs 
[128]. To achieve this purpose, standard methods of 
sample collection, storage, RNA isolation, sequencing 
and data evaluation are necessary to translate 
laboratory findings into tangible clinical applications 
[129]. In this sense, in spite of constant revolutionary 
advances in miRNA research, new horizons on the 
field of cancer research must be pursued to establish 
circulating miRNAs as cornerstone of precision 
medicine. 





In recent years, the promise of saliva as a 
diagnostic tool has aroused great interest in 
oncological research. The salivary secretome 
represents an attractive source of potential novel 
tumour markers for diagnosis and monitoring of 
cancer. MiRNAs together with the proteome, 
transcriptome, metabolome and microbiome 
represent the five diagnostic alphabets of saliva. 
Salivary miRNAs have emerged as specific group of 
biomolecules with high value as diagnostic salivary 
biomarkers of cancer. Noticeably, further research on 
salivary miRNAs is necessary to establish an effective 
saliva-based diagnostic test. Future medical research 
should address the following objectives: 1) identify 
miRNAs with high sensitivity and specificity; 2) 
analyse miRNAs in well-designed studies (discovery, 
verification and validation phases) with well 
characterised and well-matched clinical groups; 3) 
establish a gold standard normalization method; 4) 
evaluate the expression profiles of salivary miRNAs 
in other body fluids (e.g. serum, plasma and urine); 
and 5) evaluate potential uses of salivary miRNAs in 
establishing prognosis and monitoring disease as well 
as in diagnosis. In conclusion, future research should 
be directed towards finding specific salivary miRNAs 
that can be used to individualise the management of 
cancer patients. 
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